Ethyl loflazepate as a treatment for patients with idiopathic and psychogenic taste disorder.
Biopsychosoc Med
; 16(1): 16, 2022 Aug 08.
Article
em En
| MEDLINE
| ID: mdl-35941665
ABSTRACT
BACKGROUND:
Ethyl loflazepate (EL) is a benzodiazepine derivative that has been reported to activate the gustatory cortex. Our department routinely uses EL as a first-line treatment for idiopathic and psychogenic taste disorders, although little has been reported in the literature with respect to patient outcomes, so we conducted a retrospective study examining its safety and efficacy.METHODS:
Between 2008 and 2020, 49 patients (14 males and 35 females; mean age, 62.1 years) were diagnosed with taste disorders and received EL as their only treatment for > 14 days. Severity of taste disorder was evaluated using the paper disc method by Sakai et al., and treatment efficacy was evaluated using the Visual Analog Scale, wherein patients gave subjective ratings for their symptoms (reductions by > 50% after administration of EL for 4 weeks were defined as improvements).RESULTS:
Results showed that the improvement rates for patients with idiopathic and psychogenic taste disorders were 55 and 70%, respectively. Additionally, the majority (78%) improved within 2 weeks, and side effects were mild (seven cases with drowsiness and one case with dizziness).CONCLUSIONS:
We conclude that EL is an appropriate first-line medication for patients with idiopathic and psychogenic taste disorders.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Observational_studies
Idioma:
En
Revista:
Biopsychosoc Med
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Japão